# A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

> **NCT03648827** · PHASE2 · COMPLETED · sponsor: **PTC Therapeutics** · enrollment: 20 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT03648827
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-21
- **Primary completion:** 2020-10-23
- **Final completion:** 2020-10-23
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03648827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03648827, "A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03648827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*